Gut microbial dysbiosis caused by ATB therapy significantly reduces the number of activated DCs in tumor‐draining lymph nodes (TDLNs), decreases the density of effector CD8+ T cells in mesenteric lymph nodes (MLNs) and TDLNs, and ultimately weakens the host's antitumor immune response [87]. This evidence concerns the gene CD8A and neoplasm.